Ignite Creation Date:
2025-12-24 @ 9:43 PM
Ignite Modification Date:
2026-01-02 @ 9:32 AM
Study NCT ID:
NCT05936632
Status:
COMPLETED
Last Update Posted:
2024-06-11
First Post:
2023-06-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Preferences for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009369', 'term': 'Neoplasms'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'OTHER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 998}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2023-07-07', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-06', 'completionDateStruct': {'date': '2023-07-20', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-06-10', 'studyFirstSubmitDate': '2023-06-26', 'studyFirstSubmitQcDate': '2023-07-04', 'lastUpdatePostDateStruct': {'date': '2024-06-11', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2023-07-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-07-20', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Preferences for treatment attributes and trade-offs between attributes.', 'timeFrame': 'Through study completion, an average of 4-8 weeks.', 'description': 'Preferences for different treatment attributes (including clinical uncertainty and wait time), and trade-offs between these, using a study-specific Discrete Choice Experiment (DCE) Questionnaire. Preferences are measured on relative utility scale (arbitrary units, no min/max). Utility indicates preference e.g., higher values are more preferred (better).'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Discrete Choice Experiment'], 'conditions': ['Cancer']}, 'referencesModule': {'references': [{'pmid': '39571597', 'type': 'DERIVED', 'citation': 'Forrest R, Lagarde M, Aggarwal A, Naci H. Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. Lancet Oncol. 2024 Dec;25(12):1635-1643. doi: 10.1016/S1470-2045(24)00596-5. Epub 2024 Nov 18.'}]}, 'descriptionModule': {'briefSummary': 'To provide timely access to new treatments, some eligible drugs can be approved despite uncertainty surrounding the level of clinical benefit they offer patients.\n\nIt is not currently known if (and under which circumstances) people would prefer to wait to access some new drugs in exchange for greater certainty surrounding their clinical benefit.\n\nThis study aims to elicit the preferences of people in the US with experience of cancer for wait times and clinical uncertainty of new drugs.\n\nTo elicit this information, in a survey format, respondents will be presented with a hypothetical scenario and asked to state their preferences for new treatments, each with different attributes.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Online survey panel consisting of a US nationally representative sample (age, gender, income, race/ethnicity, US state).', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Individuals previously or currently diagnosed with any type of cancer.\n* Individuals with immediate family members previously or currently diagnosed with any type of cancer.\n\nExclusion Criteria:\n\n* Individuals without previous or current diagnosis with any type of cancer (themselves or immediate family members).'}, 'identificationModule': {'nctId': 'NCT05936632', 'briefTitle': 'Preferences for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.', 'organization': {'class': 'OTHER', 'fullName': 'London School of Economics and Political Science'}, 'officialTitle': 'Preferences of Individuals in the United States With Personal Experience of Cancer for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.', 'orgStudyIdInfo': {'id': '213621'}}, 'armsInterventionsModule': {'interventions': [{'name': 'Discrete Choice Experiment (DCE)', 'type': 'OTHER', 'description': 'DCE survey experiment'}]}, 'contactsLocationsModule': {'locations': [{'zip': 'WC2A 2AE', 'city': 'London', 'country': 'United Kingdom', 'facility': 'London School of Economics', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'London School of Economics and Political Science', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator', 'investigatorFullName': 'Robin Forrest', 'investigatorAffiliation': 'London School of Economics and Political Science'}}}}